Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Grimm, Juliane  [Clear All Filters]
2024
Kao Y-R, Chen J, Kumari R, Ng A, Zintiridou A, Tatiparthy M, Ma Y, Aivalioti MM, Moulik D, Sundaravel S, et al. An iron rheostat controls hematopoietic stem cell fate. Cell Stem Cell. 2024.
Schwind S, Bischof L, Bill M, Grimm J, Ussmann J, Backhaus D, Brauer D, Thanh TPham, Merz M, Franke G-N, et al. Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?. Hemasphere. 2024;8(3):e55.
2023
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, et al. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Leukemia. 2023.
2022
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LKatharina, Backhaus D, Brauer D, Goldmann K, Franke G-N, et al. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv. 2022.
2021
Grimm J, Jentzsch M, Bill M, Backhaus D, Brauer D, Küpper J, Schulz J, Franke G-N, Vucinic V, Niederwieser D, et al. Clinical Implications of SRSF2 Mutations in AML Patients undergoing Allogeneic Stem Cell Transplantation. Am J Hematol. 2021.
2019
Jentzsch DMadlen, Geus U, Grimm J, Vucinic DVladan, Pönisch DWolfram, Franke DGeorg-Niko, Behre PDr Gerhard, Niederwieser PDr Dietger, Schwind PDr Sebasti. The pre-treatment CD34+/CD38- cell burden as prognostic factor in MDS patients receiving allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019.